|
|
|
Stem Cell Related Patent Number US5928639
| Title: | Immunotherapy of cancer with allogeneic lymphocytes | | Inventors: | Slavin, Shimon; Jerusalem, Israel | | Summary: | Described herein is a method of treating a human cancer patient to eliminate residual malignant cells following a de-bulking procedure and autologous stem cell transplants. The invention addresses problems associated with minimal residual disease, which typically follows the removal of most or a substantial fraction of malignant cells from a cancer patient, after which the patient may be at risk for disease relapse due to a residual population of malignant cells that may remain viable in the patient following the de-bulking procedure. Further disclosed are methods by which an autologous stem cell transplant is performed on the patient, who is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro cytokines, immediately following partial hematopoiesis recovery. Claims of the invention include an engendered anti-malignant cell response from the infused allogeneic lymphocytes which may prevent disease relapse. | | Abstract: | Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro cytokine. The infused allogeneic lymphocytes engender an anti-malignant cell response and can be instrumental in prevention of disease relapse. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US5928639 | | Application Number: | US1996000735496 | | Date Filed: | 23/10/1996 | | Date Published: | 27/07/1999 | | Assignee: | Hadasit Medical Research Services and Development Ltd., Jerusalem, Israel |
|
|
